Form 4 for MBIO MUSTANG BIO, INC.
Accepted 2021-09-24 00:00:00 ET · period of report 2021-08-31 · accession 0001104659-21-119384 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-24 | 2021-08-31 | MBIO | Litchman Manuel MD | Pres, CEO, Dir | A - Grant | $2.58 | +2,746 | 963.0K | +0.3% | +$7,085 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK | 2021-08-31 | A | A | 2,746 | $2.58 | 962,987 | D | — | — | (F1) These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on March 1, 2021 and ending on August 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on August 31, 2021 (the purchase date of the offering period). (F2) Includes restricted stock units, which vest over various time periods. |